S100鈣結合蛋白A7(S100A7)多克隆抗體(生物素標記)
Biotin-Linked Polyclonal Antibody to S100 Calcium Binding Protein A7 (S100A7)
S100-A7; PSOR1; S100A7c; Psoriasin 1
- 編號LAC035Hu71
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源抗體標記
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物生物素
- 原抗體 PAC035Hu01-S100鈣結合蛋白A7(S100A7)多克隆抗體
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應用WB; IHC; ICC.
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 695 ¥ 1621 ¥ 2316 ¥ 5790 ¥ 23160
- 欲了解實際交易價格和更多情況，請與當地經銷商聯(lián)系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
通過ISO 9001、ISO 13485質量體系認證
特異性
該抗體是針對S100A7的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別S100A7。
用法
Western blotting: 0.5-2μg/mL
Immunocytochemistry in formalin fixed cells: 5-20μg/mL
Immunohistochemistry in formalin fixed frozen section: 5-20μg/mL
Immunohistochemistry in paraffin section: 5-20μg/mL
Optimal working dilutions must be determined by end user.
儲存
經常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
贈品
增值服務
相關產品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPC035Hu01 | S100鈣結合蛋白A7(S100A7)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APC035Hu01 | S100鈣結合蛋白A7(S100A7)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAC035Hu01 | S100鈣結合蛋白A7(S100A7)多克隆抗體 | WB |
| LAC035Hu71 | S100鈣結合蛋白A7(S100A7)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| MAC035Hu22 | S100鈣結合蛋白A7(S100A7)單克隆抗體 | WB; IHC; ICC; IP. |
| SEC035Hu | S100鈣結合蛋白A7(S100A7)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMC035Hu | S100鈣結合蛋白A7(S100A7)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Archives of Dermatological Research | Serum levels of antimicrobial peptides and proteins do not correlate with psoriasis severity and are increased after treatment with fumaric acid esters [SpringerLink: t07u24t43r357l15] |
| J Proteome Res | Proteomic Signature of Endothelial Dysfunction Identified in the Serum of Acute Ischemic Stroke Patients by the iTRAQ-Based LC–MS Approach [PubMed: 25807139] |
| Exp Dermatol | S100A7 (psoriasin) inhibits human epidermal differentiation by enhanced IL-6 secretion through IκB/NF-κB signaling [Pubmed:27060579] |
| Experimental Dermatology | S100A7 (psoriasin) inhibits human epidermal differentiation by enhanced IL‐6 secretion through IκB/NF‐κB signalling [pubmed:27060579] |
| Experiental And Therapeutic Medicine | Plasma proteins as potential targets of abnormal Savda syndrome in asthma patients treated with unique Uighur prescription [pubmed:28672924] |
| Scientific Reports | The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. [pubmed:29142248] |
| Journal of the European Academy of Dermatology and Venereology | A potential contribution of psoriasin to vascular and epithelial abnormalities and inflammation in systemic sclerosis [Pubmed:28681537] |
| Scientific Reports | Measurements of AMPs in stratum corneum of atopic dermatitis and healthy skin–tape stripping technique [Pubmed:29374283] |
| Neuroscience?Bulletin | Comprehensive proteomic profiling of patients' tears identifies potential biomarkers for the traumatic vegetative state [Pubmed:30019218] |
| Journal of Proteomics | Salivary proteins from dysplastic leukoplakia and oral squamous cell carcinoma and their potential for early detection [Pubmed: 31706945] |
| Mediators of Inflammation | Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris [] |
留言咨詢
